<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801177</url>
  </required_header>
  <id_info>
    <org_study_id>14088</org_study_id>
    <secondary_id>2004-002072-42</secondary_id>
    <secondary_id>CP11-0401</secondary_id>
    <nct_id>NCT00801177</nct_id>
  </id_info>
  <brief_title>Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy</brief_title>
  <official_title>Phase I Study of the Fully Human Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody IMC-11F8 in Patients With Solid Tumors Who Have Failed Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImClone LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImClone LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if IMC-11F8 is safe for patients, and also to
      determine the best dose of IMC-11F8 to give to patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to establish the safety profile and the maximum tolerated dose
      (MTD) of the fully human anti-EGFR monoclonal antibody IMC-11F8 in patients with solid tumors
      who have filed standard therapy or for whom no standard therapy is available.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Approximately 24 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of IMC-11F8</measure>
    <time_frame>Approximately 24 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the Time Concentration Curve (AUC)</measure>
    <time_frame>Approximately 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>Approximately 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t 1/2)</measure>
    <time_frame>Approximately 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Anti-IMC-11F8 Antibody Assessment</measure>
    <time_frame>Approximately 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Antitumor Activity</measure>
    <time_frame>Approximately 24 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>IMC-11F8 (Every week)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle of therapy administered intravenously, once a week for 6 weeks, for a total of six doses per cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMC-11F8 (Every other week)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle of therapy administered intravenously, every other week for 6 weeks, for a total of three doses per cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-11F8</intervention_name>
    <description>Cohort 1
100 mg I.V.</description>
    <arm_group_label>IMC-11F8 (Every week)</arm_group_label>
    <other_name>necitumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-11F8</intervention_name>
    <description>Cohort 2
200 mg I.V.</description>
    <arm_group_label>IMC-11F8 (Every week)</arm_group_label>
    <other_name>necitumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-11F8</intervention_name>
    <description>Cohort 3
400 mg I.V.</description>
    <arm_group_label>IMC-11F8 (Every week)</arm_group_label>
    <other_name>necitumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-11F8 I.V.</intervention_name>
    <description>Cohort 4
600 mg I.V.</description>
    <arm_group_label>IMC-11F8 (Every week)</arm_group_label>
    <other_name>necitumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-11F8</intervention_name>
    <description>Cohort 5
800 mg I.V.</description>
    <arm_group_label>IMC-11F8 (Every week)</arm_group_label>
    <other_name>necitumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-11F8</intervention_name>
    <description>Cohort 6
1000 mg I.V.</description>
    <arm_group_label>IMC-11F8 (Every week)</arm_group_label>
    <other_name>necitumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-11F8</intervention_name>
    <description>Cohort 1
100 mg I.V.</description>
    <arm_group_label>IMC-11F8 (Every other week)</arm_group_label>
    <other_name>necitumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-11F8</intervention_name>
    <description>Cohort 2
200 mg I.V.</description>
    <arm_group_label>IMC-11F8 (Every other week)</arm_group_label>
    <other_name>necitumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-11F8</intervention_name>
    <description>Cohort 3
400 mg I.V.</description>
    <arm_group_label>IMC-11F8 (Every other week)</arm_group_label>
    <other_name>necitumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-11F8</intervention_name>
    <description>Cohort 4
600 mg I.V.</description>
    <arm_group_label>IMC-11F8 (Every other week)</arm_group_label>
    <other_name>necitumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-11F8</intervention_name>
    <description>Cohort 5
800 mg I.V.</description>
    <arm_group_label>IMC-11F8 (Every other week)</arm_group_label>
    <other_name>necitumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMC-11F8</intervention_name>
    <description>Cohort 6
1000 mg I.V.</description>
    <arm_group_label>IMC-11F8 (Every other week)</arm_group_label>
    <other_name>necitumumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-confirmed, EGFR-detectable or EGFR-undetectable,
             unidimensionally-measurable and/or evaluable solid tumors who failed standard therapy
             or for whom no standard therapy is available. Patients who do not have tissue
             available for EGFR testing will undergo a biopsy of an accessible tumor.

          -  ECOG performance status score of ≤ 2 at study entry.

          -  Able to provide written informed consent.

          -  White blood cell (WBC) count ≥ 3 x 109/L; an absolute neutrophil count ≥ 1.5 x 109/L;
             a hemoglobin level &gt; 90 g/L; and a platelet count ≥ 100 x 109/L.

          -  Adequate hepatic function as defined by:

               -  an alkaline phosphatase level ≤ 5.0 x the ULN

               -  a bilirubin level ≤ 1.5 x the ULN

               -  aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤ 2.5 x the
                  ULN or ≤ 5 x the ULN for patients with liver metastases

          -  Adequate renal function as defined by a serum creatinine level within normal limits.

          -  Use of effective contraception if procreative potential exists.

          -  Life expectancy of approximately 3 months in the opinion the opinion of the
             investigator.

        Exclusion Criteria:

          -  Chemotherapy, radiation, and/or hormonal therapy (except palliative radiation therapy
             for disease-related pain and chronic hormonal therapy for prostate carcinoma) within 4
             weeks of study entry.

          -  Concurrent unstable or uncontrolled medical disease (e.g., active uncontrolled
             systemic infection, poorly controlled hypertension or history of poor compliance with
             an anti-hypertensive regimen, unstable angina, congestive heart failure, uncontrolled
             diabetes) or other chronic disease, which, in the opinion of the investigator, could
             compromise the patient or the study.

          -  Newly-diagnosed or symptomatic brain metastases (patients with a history of brain
             metastases must have received definitive surgery or radiotherapy, be clinically
             stable, and not taking steroids; anticonvulsants are allowed).

          -  Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the
             cervix. Patients with a previous malignancy but without evidence of disease for ≥ 3
             years will be allowed to enter the trial.

          -  Any condition that prevents the patient from providing informed consent.

          -  Pregnancy (confirmed by serum beta human chorionic gonadotropin [ßHCG]) or
             breast-feeding.

          -  Any investigational agent(s) or device(s) within 4 weeks of study entry.

          -  Prior treatment with cetuximab, or any other epidermal growth factor receptor
             inhibitors, including tyrosine kinase inhibitors, such as gefitinib or erlotinib.
             Prior treatment with other monoclonal antibodies targeting receptors other than the
             EGFR is permitted ≥ 4 weeks prior to study entry.

          -  Any prior therapy that targeted the EGFR or EGFR pathway.

          -  Known history of human immunodeficiency virus.

          -  Employees of the investigator or study center with direct involvement in this study or
             other studies under the direction of the investigator or study center, as well as
             family members of the employees.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E-mail: ClinicalTrials@ ImClone.com</last_name>
    <role>Study Chair</role>
    <affiliation>ImClone LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Kuenen B, Witteveen E, Ruijter R, Ervin-Haynes A, Tjin-A-ton M, Fox F, et al. A phase I study of IMC-11F8, a fully human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors. Interim results. [abstract 3024 and poster presentation]. American Society of Clinical Oncology Annual Meeting. 2006 June 2-6; Atlanta, GA.</citation>
  </results_reference>
  <results_reference>
    <citation>Kuenen B, Witteveen PO, Ruijter R, Tjin-A-Ton M, Youssoufian H, Rowinsky E, et al. A phase I study of IMC-11F8, a recombinant human anti-epidermal growth factor receptor IgG1 monoclonal antibody in patients with solid tumors. [abstract B52 and poster presentaton] International Conference on Molecular Targets and Cancer Therapeutics 2007 Oct 22-26; San Francisco, CA.</citation>
  </results_reference>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>October 11, 2010</last_update_submitted>
  <last_update_submitted_qc>October 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>ImClone LLC</organization>
  </responsible_party>
  <keyword>Tumors</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

